A recent study presented at the 2022 American College of Obstetricians & Gynecologists' Annual Clinical & Scientific Meeting found that there was neither a decreased nor increased risk for postpartum depression in patients who received hormonal contraception due to insufficient evidence.
A recent study investigated the association between immediate postpartum hormonal contraceptives and postpartum depression, according to an abstract presented at the 2022 American College of Obstetricians & Gynecologists' Annual Clinical & Scientific Meeting held in San Diego, California from May 6-8.1
“Immediate postpartum contraception, including long-acting reversible contraception (LARC) placement, is convenient, effective, and becoming more accessible given ongoing reimbursement changes,” wrote the authors.
While some hormonal contraceptives have been linked to mood changes outside of the peripartum period, these contraceptives have not been fully studied in the postpartum period, according to the authors
Shailly Prasad, MD, a resident physician at Mount Sinai Health System in New York, New York, along with fellow Icahn School of Medicine at Mount Sinai researchers Gabriela Frid, BS, an MD candidate; Jacqueline Roig, an MD candidate; Britt Lunde, MD, MPH, assistant professor; and Nina M. Molenaar, MD, PhD, conducted a retrospective cohort study on patients at their postpartum visit from January 1, 2016 to June 30, 2019, at a hospital-based outpatient clinic.
Study participants were separated into 3 arms: hormonal contraceptives, nonhormonal contraceptives, and no contraceptives.
The primary outcome of the study was measured by Edinburgh Postnatal Depression Scale (EPDS) score, which uses a cut-off score of 13 to determine depressed from nondepressed women.
Data were collected at the postpartum visit (typically 4-10 weeks following delivery). Additionally, a multivariate analysis was conducted to control for confounders such as the history of mood disorders and psychiatric medications, multiparity, and neonatal outcomes.
Results of the study found that of 1,041 patients analyzed, the immediate postpartum hormonal contraceptive use rate was 14.6%. Researchers also discovered that across the 3 study arms, there was no difference in the mean or median EPDS score.
Ultimately, the authors concluded there was neither a decreased nor increased risk for postpartum depression in patients who received hormonal contraception as there was insufficient evidence to determine that the rate of EPDS.12 or EPDS as a continuous variable was significantly different between the study arms.
Reference
1. Prasad S, Frid G, Roig J, Lunde B, Molenaar NM. Immediate postpartum hormonal contraceptives and their association with postpartum depression [A12]. Presented at: 2022 American College of Obstetrics and Gynecology Annual Clinical & Scientific Meeting. May 6 to May 8, 2022.
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Treating heavy menstrual bleeding: Levonorgestrel system vs combined oral contraceptives
November 8th 2023In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.
Read More
Enhancing contraceptive use among female smokers
October 26th 2023Women of reproductive age often use combined hormonal contraceptives, which are available orally, as a vaginal ring, or as a transdermal patch. However, CHCs are associated with increased risks of venous thromboembolism and myocardial infarction (MI).
Read More